Skip to content

EBIT at other companies

Neogen logo
NeogenNEOG
-$3.3M-161%
Balchem logo
BalchemBCPC
$55.63M+9.0%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-$789.47M-5,100%
Merck & Co. logo
Merck & Co.MRK
Zoetis logo
ZoetisZTS
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$383.5M+10.3%
Gross profit$125.7M+20.2%
Operating income$44.7M+33.2%
Net income$24.0M+15.1%
EPS (diluted)$0.59+15.7%

Balance sheet

See full
Cash & equivalents$54.9M-9.0%
Total debt$32.3M+27.8%
Total equity$361.8M+36.0%
Total assets$1.4B+9.7%

Cash flow

See full
Operating cash flow$16.2M-62.4%
CapEx$15.3M+97.7%
Free cash flow$890.0K-97.5%

Valuation

See full
Market cap$1.27B+31.4%
Enterprise value$1.25B+33.9%
P/E13.4×-17.1×
P/S0.9×0.0×

Profitability

See full
Gross margin32.5%+0.9pp
Operating margin12%+4.0pp
Net margin6.3%+3.7pp
FCF margin0.9%-3.3pp

Returns & leverage

See full
Return on equity30.3%+18.5pp
Debt / equity0.1×0.0×
Current ratio3.2×+0.3×

Where this comes from

Calculated from Phibro Animal Health’s reported figures.

The official record: Phibro Animal Health’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Phibro Animal Health's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Phibro Animal Health's EBIT?
Phibro Animal Health (PAHC) reported EBIT of $44.65M in Q1 2026.
How has Phibro Animal Health's EBIT changed year-over-year?
Phibro Animal Health's EBIT increased by 33.2% year-over-year, from $33.52M to $44.65M.
What is the long-term trend for Phibro Animal Health's EBIT?
Over 4 years (2021 to 2025), Phibro Animal Health's EBIT has grown at a 10.2% compound annual growth rate (CAGR), from $74.87M to $110.47M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.